ClinicalTrials.gg
RecruitingNCT07339722Updated Nov 5, 2026

A Study of LY4515100 in Healthy Participants

A Phase 1 interventional study of LY4515100 via SAD and LY4515100 via MAD in Healthy, sponsored by Eli Lilly and Company. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Nov 5, 2026Enrollment updatedEligibility revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to assess the safety and tolerability of LY4515100 when given orally to healthy participants. LY4515100 will be given by itself or with other medicines. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will have 3 parts and will last about 50 days. For each participant in Part A, the study will include a stay in the Clinical Research Unit (CRU) lasting about 6 days. For each participant in Part B, the study will include a stay in the CRU lasting about 15 days. For each participant in Part C, the study will include up to 2 stays in the CRU each lasting between 7-28 days.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 5, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and cardiac monitoring.
  • Have a (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
  • Individuals not of (INOCBP) may participate in this trial.
  • Participants in the Combined Oral Arm of Part C only:

    • must be 18 to 45 years of age (inclusive).
    • have a BMI within the range of 18.5 to 30 kg/m².
    • may be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).

Exclusion criteria

Exclusion Criteria:

  • Have donated 500 milliliters (mL) of blood within 30 days prior to dosing.
  • Have participated within the last 30 days in a clinical study involving an medicinal product. If the previous investigational product (IP) has a long half-life, 5 half-lives or 30 days (whichever is longer) should have passed.
  • Participants with outside of the local laboratory normal reference range for age and sex, which is judged to be by the investigator.
  • Participants with an estimated less than (\<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
  • Have a 12-lead (ECG) abnormality that, in the opinion of the investigator,
  • increases the risks associated with participating in the study
  • may confound ECG data analysis
  • Have used or intend to use over-the-counter or prescription medication including dietary or herbal medications within 7 days, or 14 days if the medication is a potential enzyme inducer, or 5 half-lives (whichever is longer), prior to dosing.
  • Smoke more than 10 cigarettes per day or the equivalent, including electronic cigarettes, and are unable to abide by investigative site smoking restrictions.
  • Have an average weekly alcohol intake that exceeds 14 units per week (males 65 years of age or younger) and 7 units per week (females and males greater than 65 years of age, if applicable)
  • Show evidence of
  • (HIV) infection and/or positive human HIV antigen and/or antibodies
  • and/or positive hepatitis C antibody
  • and/or positive hepatitis B surface antigen.
  • Have liver disease.
  • Any clinical condition or procedure (for example, gastrointestinal obstruction, gastric bypass, or cholecystectomy) that may affect the absorption, distribution, or excretion of the study drug and confound pharmacokinetics (PK) assessment.
  • Part C Only:

    • Have history of neuropathy of any cause.
    • Have impaired hearing or a history of hearing problems.
    • Have any medical conditions, medical history, or are taking any medications that are in the itraconazole prescribing information, such as prior history of to itraconazole or other azoles.
    • Participants with any known history of thyroid disease
  • Participants in the Combined Oral Arm of Part C only:

    • Are current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
    • Are at high risk for arterial or venous thrombotic diseases, disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
    • Have abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
    • Have undiagnosed abnormal uterine bleeding.
    • Have any history of breast, uterine or ovarian cancer.
    • Use of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
    • Have contraindications for the use of levonorgestrel/ethinyl estradiol.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
209 participants (estimated)

Study arms

  • Experimental
    LY4515100 of Part A (SAD)

    Single-ascending doses of LY4515100 will be given orally

    Drug: LY4515100 via SAD

  • Experimental
    LY4515100 of Part B (MAD)

    Multiple-ascending doses of LY4515100 will be given orally

    Drug: LY4515100 via MAD

  • Experimental
    LY4515100 and Itraconazole of Part C

    LY4515100 and Itraconazole will be given orally

    Drug: LY4515100 · Drug: Itraconazole

  • Experimental
    LY4515100 and Metformin of Part C

    LY4515100 and Metformin will be given orally

    Drug: LY4515100 · Drug: Metformin

  • Experimental
    LY4515100 and Transporter Substrates or Renal Marker of Part C

    LY4515100 and Transporter Substrates or Renal Marker will be given either orally or intravenously (IV)

    Drug: LY4515100 · Drug: Caffeine · Drug: Digoxin · Drug: Iohexol · Drug: Rosuvastatin

  • Experimental
    LY4515100 and Midazolam of Part C

    LY4515100 will be given orally. Midazolam will be given orally and IV.

    Drug: LY4515100 · Drug: Midazolam

  • Experimental
    LY4515100 and Combined Oral Contraceptive of Part C

    LY4515100, Levonorgestrel, and Ethinyl Estradiol will be given orally

    Drug: LY4515100 · Drug: Levonorgestrel · Drug: Ethinyl Estradiol

  • Placebo comparator
    Placebo Part A

    Placebo will be given orally

    Drug: Placebo

  • Placebo comparator
    Placebo Part B

    Placebo will be given orally

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100 in Parts A and B

    SAEs of LY4515100

    Time frame: Day 1 up to Day 30

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100

    PK: AUC of LY4515100

    Time frame: Day 1 through Day 11

  2. PK: Maximum Observed Drug Concentration (Cmax) of LY4515100

    PK: Cmax of LY4515100

    Time frame: Day 1 through Day 11

  3. PK: Time of maximum observed drug concentration (tmax) of LY4515100

    PK: tmax of LY4515100

    Time frame: Day 1 through Day 11

  4. PK: Geometric Means of Area Under the Concentration-Time Curve From 0 to Infinity [AUC(0-∞)] of LY4515100 in Combination with Itraconazole versus LY4515100 Alone

    Time frame: Day 1 through Day 50

  5. PK: Geometric Means of Cmax of LY4515100 in Combination with Itraconazole versus LY4515100 Alone

    Time frame: Day 1 through Day 50

  6. PK: Geometric Means of AUC(0-∞) of Substrate in Combination with LY4515100 versus Substrate Alone

    Time frame: Day 1 through Day 36

  7. PK: Geometric Means of Cmax of Substrate in Combination with LY4515100 versus Substrate Alone

    Time frame: Day 1 through Day 36

07

Study locations

1 of 2 sites recruiting
  • Fortrea Clinical Research Unit
    Dallas, Texas 75247, United States
    Recruiting
    • · Contact866-429-3700
    • Gene Voskuhl · Principal investigator
  • Fortrea Clinical Research Unit
    Madison, Wisconsin 53704, United States
    Not yet recruiting
    • · Contact866-429-3700
    • Kimberly Cruz · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Mar 2027, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 14, 2026
StartActual
Jan 15, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Fortrea Clinical Research Unit · Madison, United States
Nov 5, 2026
Enrollment
123→209
Nov 5, 2026
Eligibility
1 inclusion criterion edited, 4 added; 1 exclusion criterion edited, 8 added
What changed in the criteria
Inclusion criteria
  • EditedHave a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
  • AddedParticipants in the Combined Oral Contraceptive Arm of Part C only:
  • Addedmust be 18 to 45 years of age (inclusive).
  • Addedhave a BMI within the range of 18.5 to 30 kg/m².
  • Addedmay be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
Exclusion criteria
  • EditedParticipants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
  • AddedParticipants in the Combined Oral Contraceptive Arm of Part C only:
  • AddedAre current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
  • AddedAre at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
  • AddedHave abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
  • AddedHave undiagnosed abnormal uterine bleeding.
  • AddedHave any history of breast, uterine or ovarian cancer.
  • AddedUse of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
  • AddedHave contraindications for the use of levonorgestrel/ethinyl estradiol.
Nov 5, 2026
Interventions
Added Drug: Midazolam·Drug: Levonorgestrel·Drug: Ethinyl Estradiol. Arms added: LY4515100 and Midazolam of Part C·LY4515100 and Combined Oral Contraceptive of Part C
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    1 site added
    Show site
    • Fortrea Clinical Research Unit · Madison, United States
    Enrollment 123→209
    Eligibility 1 inclusion criterion edited, 4 added; 1 exclusion criterion edited, 8 added
    What changed in the criteria
    Inclusion criteria
    • EditedHave a body mass index (BMI) within the range of 18.5 to 32.0 kilograms per square meter (kg/m²) (inclusive).
    • AddedParticipants in the Combined Oral Contraceptive Arm of Part C only:
    • Addedmust be 18 to 45 years of age (inclusive).
    • Addedhave a BMI within the range of 18.5 to 30 kg/m².
    • Addedmay be healthy pre-menopausal assigned female at birth (AFAB) individuals of child bearing potential (IOCBP).
    Exclusion criteria
    • EditedParticipants with an estimated glomerular filtration rate less than (<) 90 milliliter per minute per 1.73 square meters (mL/min/1.73 m²).
    • AddedParticipants in the Combined Oral Contraceptive Arm of Part C only:
    • AddedAre current smokers or have used nicotine, including tobacco or nicotine replacement products within 14 days prior to the first dose of combined oral contraceptive (COC), or plan to use nicotine, including tobacco or nicotine replacement products during the study.
    • AddedAre at high risk for arterial or venous thrombotic diseases, autoimmune disease with lupus anticoagulants or anti-phospholipid syndrome, major surgery within the past 3 months, anticipated prolonged immobility.
    • AddedHave abnormalities indicative of increased risk of VTE on the thrombophilia panel at screening.
    • AddedHave undiagnosed abnormal uterine bleeding.
    • AddedHave any history of breast, uterine or ovarian cancer.
    • AddedUse of Vitamin C (greater than or equal to (≥) 500 mg/day) or acetaminophen within 14 days before dosing.
    • AddedHave contraindications for the use of levonorgestrel/ethinyl estradiol.
    Interventions Added Drug: Midazolam·Drug: Levonorgestrel·Drug: Ethinyl Estradiol. Arms added: LY4515100 and Midazolam of Part C·LY4515100 and Combined Oral Contraceptive of Part C
    + 3 other changes: index terms, verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07339722
Responsible party
Sponsor
First posted
Jan 14, 2026
Start date
Jan 15, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4515100

Start the discussion